An ACTH-Producing Neuroendocrine Tumor: Clinical Course of Multidisciplinary Therapy Including Peptide Receptor Radionuclide Therapy - A Case Report. [PDF]
Koizumi T +10 more
europepmc +1 more source
Editorial: Women in radionuclide therapy: 2023
Egesta Lopci, Federica Matteucci
doaj +1 more source
Neoadjuvant therapy with peptide receptor radionuclide therapy for pancreatic neuroendocrine tumours. [PDF]
Hallet J, Søreide K.
europepmc +1 more source
PReCedeNT trial: Phase III randomized-controlled trial of Lutetium - 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs). [PDF]
Puranik AD +21 more
europepmc +1 more source
Retraction: Efficacy and Safety of Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis of Comparative Studies. [PDF]
Zhao J, Pei X, Li Y.
europepmc +1 more source
Renal function affects absorbed dose to the kidneys and haematological toxicity during Lu-DOTATATE treatment [PDF]
core +1 more source
Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours. [PDF]
Kuiper J +4 more
europepmc +1 more source
Radiopharmaceutical formulation and preliminary clinical dosimetry of [177Lu]Lu-DOTA-MGS5 for application in peptide receptor radionuclide therapy. [PDF]
Zavvar TS +12 more
europepmc +1 more source
Preclinical Investigation of [212Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model. [PDF]
Saidi A +3 more
europepmc +1 more source

